Grafa News and Videos — Page 788

NIO (NYSE:NIO) reported a 112.2% surge in first-quarter revenue for 2026, driven by a near-doubling of vehicle deliveries and vastly improved manufacturing margins that pushed the company’s adjusted net results into profitability.

Parker Hannifin (NYSE:PH) has signed a definitive agreement to acquire CIRCOR Aerospace from KKR and CIRCOR International, Inc. for a cash purchase price of $2.55 billion, marking a significant expansion for the industrial giant's flight-critical components division.

Hovnanian Enterprises (NYSE:HOV) reported a small net loss for its second fiscal quarter that nevertheless came in ahead of internal operating guidance, as resilient homebuyer traffic helped the national homebuilder mitigate ongoing margin compression and affordability hurdles.

United Maritime (NASDAQ:USEA) reported a sharp reduction in its first-quarter net loss alongside a return to positive adjusted earnings, driven by a strategic fleet reallocation into the higher-earning Capesize dry bulk sector and substantial capital recycling.

Cosmos Health (NASDAQ:COSM) generated record revenue in the first quarter of 2026, driven by sustained distribution gains and market expansions, even as a shifting business mix and operational investments weighed on bottom-line profitability.

Williams-Sonoma (NYSE:WSM) reported solid top-line momentum for its first fiscal quarter, driven by positive comparable brand revenue across its portfolio, though elevated import tariff expenses weighed on the retailer's gross margins.

Immix Biopharma (NASDAQ:IMMX) announced a highly favorable interim update from its ongoing registrational Phase 2 NEXICART-2 clinical trial, showing that its investigational CAR-T cell therapy, NXC-201, achieved a 95% complete response rate in patients with relapsed or refractory AL Amyloidosis.

HUTCHMED (NASDAQ:HCM) and Innovent Biologics jointly announced that China’s National Medical Products Administration has approved the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) for the treatment of adults with advanced kidney cancer.

Scienjoy (NASDAQ:SJ) reported a successful turnaround in its bottom-line profitability for the first quarter of 2026, recovering from a prior-year loss even as total revenues experienced a moderate single-digit contraction.

Origin Agritech (NASDAQ:SEED) reported a 31.9% decline in revenue for the first half of fiscal 2026, reflecting a deliberate structural transition within its commercial seed portfolio, though aggressive corporate cost-saving initiatives allowed the company to significantly narrow its net loss.